The European population is aging rapidly which poses a challenge on the individual, the European societies, and health care systems. Among the most promising public health interventions that may extend healthy life expectancy at older age are vitamin D, marine omega-3 fatty acids and physical exercise. However, their individual and combined effects have yet to be confirmed in a clinical trial. The broad aim of DO-HEALTH is to prolong healthy life expectancy in European seniors. The specific aim is to establish whether vitamin D, omega-3 fatty acids, and a simple home exercise program will prevent disease at older age. To achieve these aims, DO-HEALTH will enroll 2152 community-dwelling men and women who are 70 years and older, an age when chronic diseases increase substantially. The DO-HEALTH seniors will be recruited from 7 European cities (Zurich, Basel, Geneva, Toulouse, Berlin, Innsbruck and Coimbra) and will be randomized in a 2x2x2 factorial design trial to a simple home exercise program and/or vitamin D, and/or omega-3 fatty acids, over a 3 year period. This will allow to test the individual and the combined benefit of the interventions in the prevention of 5 primary endpoints: incident non-vertebral fractures; functional decline; systolic and diastolic blood pressure change; cognitive decline; and the rate of any infection. Key secondary endpoints include incidence of hip fractures, rate of falls, severity of pain in symptomatic knee osteoarthritis, gastro-intestinal symptoms, mental and oral health, quality of life, and mortality. All clinical endpoints will be supported by a large DO-HEALTH biomarker study to evaluate the effect of the interventions at the cellular level of multi-organ function. DO-HEALTH will further evaluate reasons why or why not seniors adhere to the 3 interventions, and will assess their cost-benefit in a health economic model based on documented health care utilization and observed incidence of chronic disease. website DO-HEALTH: http://do-health.eu/wordpress/
The 3 primary treatment comparisons are: 1. 2000 IU vitamin D per day compared to placebo (controlling for the other treatment strategies) 2. 1 g of omega-3 fatty acids (EPA+DHA, ratio 1:2, from marine algae) compared to placebo (controlling for the other treatment strategies) 3. Home exercise program (muscle strength) of 30 minutes 3 times a week compared to a control exercise program (joint flexibility) 30 minutes 3 times a week Follow-up: DO-HEALTH seniors will be followed for 3 years, in-person, and in 3-monthly intervals (4 clinical visits and 9 phone calls) at the 7 recruitment centers. Study population: DO-HEALTH will enroll seniors age 70 years and older. To represent the largest part of the senior population, DO-HEALTH will recruit community-dwelling seniors. However, to represent also the pre-frail population at risk of institutionalization, at least 40% of seniors will be enrolled based on a fall with or without a fracture in the year before DO-HEALTH enrolment. Study Design: This is a randomized, double-blind, placebo-controlled, 2×2×2 factorial design clinical trial. Recruitment Centers: The trial will be performed at 7 recruitment centers located in 5 countries: Switzerland (University of Zurich, Basel University Hospital, Geneva University Hospital), France (University of Toulouse Hospital Centre), Germany (Charité Berlin), Portugal (University of Coimbra), and Austria (Innsbruck Medical University). Randomization: Stratified block randomization. Labeling of study intervention will be performed by a central randomization centre in Switzerland. Stratification variables: recruitment centre (7 centers), fall during previous 12 months (yes/no), gender, and age (70 - 84 and 85+). At least 40% of Seniors among those who fell or did not fall during the last year will be enforced at each of the 7 recruitment centers. Gender and age distribution will be monitored within each recruitment centre with the DO-HEALTH randomization software. If gross imbalance (less than 30% of fallers/non-fallers in a stratum) is detected within a centre, recruitment strategies for the centre will be adapted to boost recruitment of participants of underrepresented category. website DO-HEALTH: http://do-health.eu/wordpress/
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
2,157
2000 IU/d
Ratio EPA:DHA = 1:2 1 g/d
University of Innsbruck
Innsbruck, Austria
University of Toulouse - Centre de Recherche - Gérontopôle Hôpital La Grave
Toulouse, France
Charité Berlin
Berlin, Germany
University of Coimbra - Clínica Universitária de Reumatologia
Coimbra, Portugal
Centre on Aging and Mobility, University of Zurich and City Hospital Waid
Zurich, Canton of Zurich, Switzerland
Basel University
Basel, Switzerland
Hôpitaux Universitaires de Genève
Geneva, Switzerland
Bone: Incident non-vertebral fractures over 36 months
Confirmed by medical and/or x-ray reports
Time frame: over 36 months
Muscle: Functional decline (lower extremity function)
Measured with the SPPB (short physical performance test battery)
Time frame: Baseline, 12, 24 and 36 months
Cardio-vascular: Systolic and diastolic blood pressure change
Standardized blood pressure assessment in sitting position
Time frame: Baseline, 12, 24 and 36 months
Brain: Cognitive decline
Montreal Cognitive Assessment (MoCA)
Time frame: Baseline, 12, 24 and 36 months
Immunity: Rate of any infections
3-monthly incident infection protocol
Time frame: Baseline, and every 3 months up to 36 months
Bone: Incident hip fractures
Based on medical records and/or x-ray reports
Time frame: 36 months
Bone: Incident total fractures
Combined non-vertebral and vertebral fractures among subgroup of 1502 participants with DXA vertebral morphometry assessment
Time frame: 36 months
Bone: Incident vertebral fractures
Based on DXA vertebral morphometry among subset of 1502 participants
Time frame: 36 months
Bone: Bone mineral density decrease at the lumbar spine and hip
Assessed in a subset of 1502 participants with DXA measurements
Time frame: Baseline, 12, 24, and 36 months
Muscle: Rate of falls
Any low trauma fall, injurious fall
Time frame: Assessed every 3 months over 36 months
Muscle: reaction time and grip strength
Reaction time will be assessed with the repeated sit-to-stand test; grip strength will be assessed with the Martin Vigorimeter
Time frame: Baseline, 12,24,36 months
Muscle: Muscle mass decrease at upper and lower extremities
Subset of 1502 participants with DXA measurements
Time frame: Baseline, 12,24,36 months
Muscle: Dual tasking 10-meter gait speed
Time frame: Baseline, 12,24 and 36 months
Muscle/Bone: musculoskeletal pain
Assessed with the McGill questionnaire
Time frame: Baseline, 12,24, and 36 months
Cardio-vascular: Incident Hypertension
Time frame: 36 months
Brain: mental health decline
Assessed with Geriatric Depression Scale
Time frame: Baseline, 12,24, and 36 months
Brain: Incident Depression
Time frame: 36 months
Brain/Muscle: Dual tasking gait variability
Subset of 250 participants
Time frame: Baseline, 12, 24 and 36 months
Immunity: Rate of upper respiratory infections / rate of flu-like illness
Assessed with infection protocol every 3 months
Time frame: 36 months
Immunity: Incident severe infections that lead to hospital admission
Time frame: 36 months
Cartilage/Bone: Severity of knee pain in participants with symptomatic knee osteoarthritis
Assessed with the KOOS questionnaire. Knee OA assessment with modified ACR criteria.
Time frame: Baseline, 12, 24 and 36 months
Cartilage/Bone: Rate of knee buckling
Questionnaire-based.
Time frame: Baseline, 12,24,36 months
Cartilage/Bone: NSAID use / number of joints with pain
Assessed by questionnaire and homunculus figure
Time frame: Baseline, 12, 24, 36 months
Dental: Decline in oral health
Assessed with questionnaire.
Time frame: Baseline, 12,24 and 36 months
Dental: Tooth loss
Assessed by tooth count at every clinical visit
Time frame: 36 months
Gastro-Intestinal: rate of GI symptoms
Assessed with ROME III questionnaire.
Time frame: Baseline, 12, 24 and 36 months
Glucose-Metabolic: Change in fasting glucose, insulin levels (QUICKI, HOMA index)
Laboratory measures at the Central DO-HEALTH Laboratory (Institute of Clinical Chemistry at the University Hospital Zurich)
Time frame: Baseline, 12,24,36 months
Glucose-Metabolic: Body composition
Subset of 1502 participants with DXA measurements
Time frame: Baseline, 12, 24, 36 months
Kidney: Decline in kidney function
Blood creatinine levels and estimated glomerular filtration rate
Time frame: Baseline, 12, 24, and 36 months
Global Health: Quality of life
Assessed with questionnaire (EuroQuol).
Time frame: Every 6 months
Global Health: Incident disability regarding activities of daily living
Assessed with HAQ-PROMIS questionnaire
Time frame: Baseline, 12, 24 and 36 months
Global Health: Incident nursing home admission
Time frame: 36 months
Global Health: Mortality
Time frame: 36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.